Our global community is at the forefront of biology and technology and is dedicated to transform healthcare and help people live healthier, better lives. Join us!
Adicet Bio, Inc. is a biotechnology company founded in 2015 focused on the development of novel off-the-shelf allogeneic gamma delta T cell immune cell therapies for oncology and other indications. resTORbio, Inc. is a public, clinical-stage biopharmaceutical company that has been focused on developing innovative medicines that target the biology of aging to treat aging-related diseases. On April 29, 2020, resTORbio and Adicet announced a reverse merger which is expected to close in the second half of 2020. The resulting publicly-traded company, “Adicet Bio”, will focus on progressing Adicet’s proprietary gamma delta T cell therapy platform. Adicet expects to initiate clinical development of ADI-001 by the end of 2020 or early 2021. Adicet’s second product candidate, ADI-002 subject to the FDA regulatory process for review of INDs, Adicet intends to file an IND and, subject to the FDA regulatory process for review of IND’s, initiate a Phase 1 clinical trial in 2021.
Adicet’s solid tumor efforts are further complemented by the company’s proprietary T cell receptor-like antibody, or TCRL, platform technology, which enables the generation of CARs that recognize tumor antigens inside tumor cells, otherwise known as intracellular proteins. Adicet believes the ability to selectively bind to tumor antigens derived specifically from intracellular proteins is a critical advantage to immunocellular therapy due to the scarcity of tumor-specific surface antigens on solid tumors. Adicet’s approach to generating CARs for some product candidates takes advantage of this ability.
SENIOR SCIENTIST, DOWNSTREAM VIRAL VECTOR GROUP
Adicet Bio is developing a next generation manufacturing process to advance our platform of “off-the-shelf” immune cell products. We are currently seeking individuals for our viral vector group as we advance our production platforms. The position offers a chance to be part of a highly motivated team, applying the latest cell culture and bioprocessing practices to facilitate development of our proprietary cell therapies.
We are currently seeking an energetic and experienced individual with a strong materials purification background to join our downstream viral vector team. The successful candidate will contribute to the advancement of Adicet’s production platform by developing, characterizing, and optimizing vector purification procedures designed to support both research and manufacturing pipelines.
The individual will serve as the technical lead for a team of junior scientists and will work in collaboration with Upstream and Analytical vector teams, Tech Ops teams, as well as external groups, in order to meet project timelines and deliver a highly consistent and robust viral vector production program.
Additional Job Responsibilities:
Downstream Viral Vector Development - Qualifications:
Adicet Bio offers both comprehensive benefits and Paid Time (PTO) plans for employees, which begin on the first day of employment, as well as the opportunity to work in a growing, dynamic environment.
Adicet Bio is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.